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1. Introduction  
Automation is nowadays implemented in many areas of the drug discovery process, from 
sample preparation through process development. High-Throughput Screening (HTS) is a 
well-established process for lead discovery that includes the synthesis and the activity 
screening of large chemical libraries against biological targets via the use of automated and 
miniaturized assays and large-scale data analysis. In recent years, high-throughput 
technologies for combinatorial and multiparallel chemical synthesis and automation 
technologies for isolation of natural products have tremendously increased the size and 
diversity of compound collections. The HTS process consists of multiple automated steps 
involving compound handling, liquid transfers and assay signal capture. Library screening 
has become an important source of hits for drug discovery programmes. Three main 
complementary methodologies are actually used: 1) in silico virtual screening of libraries to 
select small sets of compounds for biochemical assays, 2) fragment-based screening using 
high-throughput X-ray crystallography or NMR methods to discover relatively small related 
compounds able to bind the target with high efficiency and 3) HTS of either diverse 
chemical libraries or focused libraries tailored for specific gene families. Furthermore a 
variety of assay technologies continues to be developed for high-throughput screening; 
these include cell-based assays, surrogate systems using microbial cells and systems to 
measure nucleic acid-protein and receptor-ligand interactions. Modifications have been 
developed for in vitro homogeneous assays, such as time-resolved fluorescence, 
fluorescence polarization and the scintillation proximity. Innovations in engineering and 
chemistry have led to delivery systems and sensitive biosensors for Ultrahigh-Throughout 
Screening working in nanoliter and picoliter volumes. Spectroscopic methods are now 
sensitive to single molecule fluorescence. Technologies are being developed to identify new 
targets from genomic information in order to design the next generation of screenings. As 
HTS assay technologies, screening systems, and analytical instrumentation the interfacing of 
large compound libraries with sophisticated assay and detection platforms will greatly 
expand the capability to identify chemical probes for the vast untapped biology encoded by 
genomes.  
As a consequence the growing demand for new, highly effective drugs is driven by the 
identification of novel targets derived from the human genome project and from the 
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understanding of complex protein-protein interactions that contribute to the onset and 
maintaining of pathological conditions. To illustrate the dynamics of quantitative and 
qualitative process approaches to accelerated drug development, a model pipeline is 
depicted in Fig. 1. 
 
Fig. 1. Drug Discovery pipelines: IND: Investigational New Drug, CTA: Clinical Trial 
Application, NDA: New Drug Application, MAA: Marketing Authorization.  
At the basis of HTS is the simultaneous employment of different  sets of compounds that are 
rapidly screened for the identification of active components. This approach is nowadays 
regarded as a powerful tool for the discovery of new drug candidates, catalysts and 
materials. It is also largely utilized to improve the potency and/or the selectivity of existing 
active leads by producing analogues derived by systematic substitution or introduction of 
functional groups or by merging active scaffolds. In Combinatorial Chemistry (CC) the 
higher is the number of building blocks and the number of transforming synthetic steps, the 
more attainable molecules can be had. However, the higher is the number of attainable 
molecules, the higher should be the handling capacity of so many reagents and products; 
thus automation in CC plays a very critical role. Automation in chemical synthesis has been 
essentially developed around the solid phase method introduced by R. B. Merrifield  for the 
synthesis of peptides, which, after its introduction, has been continuously improved in 
terms of solid supports, linkers, coupling chemistry, protecting groups and automation 
procedures, making it nowadays one of the most robust and well-established synthetic 
methods (Shin et al., 2005). For these reasons, the basic concepts of CC, such as compound 
libraries, molecular repertoires, chemical diversity and library complexity have been 
developed using peptides and later transferred to the preparation of libraries of small 
molecules and other oligomeric biomolecules (Houghten et al., 2000). The easiness of 
preparation, characterization and the robustness of the available chemistry provide high 
purity levels and the built-in code represented by their own sequences have promoted the 
employment of large but rationally encoded mixtures instead of single compounds, leading 
to the generation and manipulation of libraries composed of hundreds of thousands and 
even millions of different sequences. The broad complexity of mixture libraries has also led 
to the development of several screening procedures based on iterative or positional 
scanning deconvolution approaches for soluble libraries. 
2. HTS 
High-throughput screening (HTS) has achieved a dominant role in drug discovery over the 
past two decades. Its aim is to identify active compounds (hits) by screening large numbers 
of diverse chemical compounds against selected targets and/or cellular phenotypes. The 
HTS process consists of multiple automated steps involving compound handling, liquid 
transfers, and assay signal capture, all of which unavoidably contribute to systematic 
variation in the screening data. It represents the process of testing a large number of diverse 
chemical structures against disease targets to identify 'hits'.  
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Compared to traditional drug screening methods, HTS is characterized by its simplicity, 
rapidness, low cost, and high efficiency, taking the ligand-target interactions as the 
principle, as well as leading to a higher information harvest.  
Independent of the precise nature of the applied screening technology, lead discovery 
efforts can always be analyzed and optimized along the same fundamental principles of 
performance management: time, costs, and quality of the process (Fig. 2).  
•time/well
•wells/day
•screens/year
•project time
Time
•few false positives
•few false negatives
•S/N, H/L, Z’-factor
•validated binders
Quality
•reagents
•consumables
•instrumentation
•personnel
Costs
 
Fig. 2. HTS “magic triangle”. 
As a multidisciplinary field, HTS involves an automated operation-platform, highly 
sensitive testing system, specific screening model (in vitro), abundant component libraries, 
and a data acquisition and processing system. Several technologies such as fluorescence, 
nuclear-magnetic resonance, affinity chromatography, surface plasmon resonance and DNA 
microarray, are actually available, and the screening of more than 100 000 samples per day 
is already possible. 
The data analysis challenge is to detect biologically active compounds from assay variability. 
Traditional plates, controls-based and non-controls-based statistical methods have been 
widely used for HTS data processing and active identification by both the pharmaceutical 
industry and academic sectors. Recently, the introduction of improved robust statistical 
methods has reduced the impact of systematic row/column effects in HTS data. In practice, 
no single method is the best hit detection method for every HTS data set. Nevertheless, to 
help in the selection of the most appropriate HTS data-processing and active identification 
methods a 3-step statistical decision methodology has been developed: Step 1) to determine 
the most appropriate HTS data-processing method and establish criteria for quality control 
review and active identification from the 3-day assay signal window and validation tests. 
Step 2) to perform a multilevel statistical and graphical review of the screening data to 
exclude data that fall outside the quality control criteria. Step 3) to apply the established 
active criterion to the quality-assured data to identify the active compounds. 
 Automation 
 
420 
The principles and methods of HTS find their application for screening of combinatorial 
chemistry, genomics, protein, and peptide libraries. For the success of any HTS assay or 
screening several steps -like target identification, reagent preparation, compound 
management, assay development and high-throughput library screening- should be carried 
out with utmost care and precision. Historically, the majority of all targets in HTS-based 
lead discovery fall into a rather small set of just a few target families (Table 1). Enzymes 
such as kinases, proteases, phosphatases, oxidoreductases, phosphodiesterases, and 
transferases comprise the majority of biochemical targets in today’s lead discovery efforts. 
Among cell-based targets, many  GPCRs (G-protein-coupled receptors, 7-transmembrane 
receptors), nuclear hormone receptors, and some types of voltage- and ligand-gated ion 
channels (e.g., Ca2+-channels) are very well suited for screening large compound 
collections. Despite the large number of human genes (>25,000) and the even larger number 
of gene variants and proteins (>100,000), the number of molecular targets with drugs 
approved against the target is still fairly limited (~350 targets). The explanations for this 
discrepancy can be due to some targets might not be feasible at all for modulation via low 
molecular weight compounds. Others, however, might simply not be approachable by 
current technologies and therefore constitute not only a great challenge but also a 
tremendous potential for future lead discovery. Among those, a large number of ion 
channels, transporters, and transmembrane receptors but also protein-protein, protein-
DNA, and protein-RNA interactions, even RNA/DNA itself, might form innovative targets 
for modulation via low molecular weight compounds. With better tools with sufficient 
predictivity, one might be able to expand the current HTS portfolio into novel classes of 
pharmaceutical targets. Besides the obvious classes with targets on the cell surface, such as 
ion channels, transporters and receptors, we predict that modulation of intracellular 
pathways, particularly via protein-protein interactions, might have a great potential for 
pharmaceutical intervention. In this regard, some modern technologies such as subcellular 
imaging (High Content Screening [HCS]) will certainly enable novel and powerful 
approaches for innovative lead discovery. 
 
Established Target Classes Novel Target Classes 
 Kinases/Phosphatases 
 Oxidoreductases 
 Transferases 
 Proteases 
 Nuclear Hormone Receptors 
 G-protein-coupled receptors, 7-
transmembrane receptors (GPCRs) 
 Ion Channels (some) 
 Signaling Pathways (some) 
 Ion Channels  
 Transporters  
 Transmembrane Receptors 
 Signaling Pathways 
 Protein-Protein Interactions 
 Protein-DNA Interactions 
 Protein-RNA Interactions 
 DNA/RNA 
Table 1. Established and potential future target classes for HTS 
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HTS not only helps in drug discovery but it is also important in improving  present drug 
moieties to optimize their activity. In past years many advances in science and technology 
and economic pressures have kept every researcher to develop speedy and precise drug 
discovery and screening technologies to tackle the ever increasing diseases and the many 
pathogens acquiring resistance to currently available drugs. This also applies to screening 
the ever increasing compound libraries waiting to be screened due to increase in the parallel 
and combinatorial chemical synthesis. Research is also carried out so to cut the drug 
development costs, so that industries keep abreast with ever increasing competition.  
2.1 Screenings of libraries 
The greatest potential of combinatorial chemistry is represented by the number and variety 
of screenable compounds. Major efforts of researchers in the last decades have been focused 
on the development of methodologies to further increase molecular diversity. An interesting 
approach is based on general reversible reactions that produce “dynamic mixtures”: in 
these, reactants and products are present in thermodynamic equilibrium. The assayed 
biological system selects the best binding structures among the different mixture 
components, thus producing a shifts of the reaction equilibrium by subtracting the product. 
Importantly, dynamic libraries do not need a deconvolution step and ligands are selected 
directly in the reaction mixture. Although innovative and promising, dynamic 
combinatorial libraries have been so far limited only to a small number of reversible 
reactions and libraries of moderate size. Similarly, the methodology named “libraries from 
libraries” has represented an innovation compared to the traditional concepts of 
combinatorial chemistry. By this approach, combinatorial libraries of peptides are built on a 
solid phase and are subsequently modified in order to maximize the chemical diversity. 
Oxidations, reductions, alkylations and acylations can be performed, exponentially 
increasing the number of new compounds. Once synthesized, libraries are employed in 
screening processes to determine active components for a given target. The choice of the 
assay is of utmost importance to succeed with a screening program. Indeed, different assays 
can be chosen depending on whether binders for an unspecified site are searched for, or 
ligands with predetermined properties are needed. Competition assays ensure the selection 
of active molecules with a specificity for the interacting interface of the proteins employed 
as targets in the screening. Binding assays can also be performed “on bead”, in this case the 
libraries have been prepared with the Mix and Split method, the use of bead bound 
molecules has the advantage of having a local high concentration of ligands (several 
picomoles on a very limited surface area). The assay principle is simple and is based on the 
interaction between molecules and a labelled target-any natural or artificial receptor, 
enzymes, antibodies, nucleic acids or even small molecules in solution. When the labelled 
target binds the bound molecule, the bead will also be labelled and therefore can be 
visualized/detected by chromogenic methods and using micromanipulators. The labeled 
bead can be isolated and the molecule/peptide microsequenced. Though the on-bead assay 
is faster and easier to perform homogeneous phase assays in solution it can provide more 
specific functional evaluations. However highly charged or very hydrophobic molecules, 
when locally highly concentrated, can result in a high number of false-positive hits. Partially 
releasable libraries, based on light sensitive chemical linkers have also been described. These 
linkers, being very resistant to cleavage under acidic conditions, allow the complete removal 
of amino acid side chain protections, while they can be easily cleaved by irradiation at a 
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defined wavelength. By tuning light intensity and duration, small amounts of peptides can 
be released in solutions, while the molecules bound to the bead can be microsequenced to 
reveal the molecule identity. The deconvolution of libraries bound to solid supports can be 
performed following different approaches. Peptide arrays can be distinguished on the basis 
of their preparations: some ones involve the immobilization of pre-synthesized peptide 
derivatives and others the in situ synthesis directly on the array surface. The pre-synthesis 
approach requires a chemoselective immobilization on solid supports that can provide a 
useful method for controlling the orientation and the density of the immobilized peptides.  
A critical factor for the screening of compound arrays is the accessibility to the immobilized 
molecules by the target proteins. Several spacers between peptides and chip surface have 
been proposed, such as 11 mercaptoundecanoic acid, hydrophilic polyethylene glycol chain, 
dextran, bovine serum albumin or human leptin and water-compatible supramolecular 
hydrogels. 
In situ parallel synthesis methods can provide cheaper and faster miniaturized spatially 
addressed peptide arrays. Two general approaches have been introduced for the 
preparation of peptide arrays on solid supports: the photolithographic and the SPOT 
synthesis. The photolithographic approach consisted in the translation of the solid phase 
method for peptide synthesis into the preparation of supported peptide arrays by mean of 
photolabile protecting groups that allow the synthesis to proceed only on defined surface 
spots that are illuminated by light at a given wavelength. In the SPOT synthesis, the 
peptides arrays are synthesized in a stepwise manner on a flat solid support, such as 
functionalized cellulose membrane, polypropylene and glass, following the standard Fmoc-
based peptide chemistry. Each spot is thus considered as an independent microreactor: 
thereby the selection of the solid support is a key factor. The support has to meet the 
chemical and the biological requirements of the target and it determines the synthesis and 
screening methods. It also dictates the functionalization type and the insertion of spacers 
and/or linkers. Described supports include ester-derivatized planar supports, CAPE 
[celluloseamino-hydroxypropyl ether] membranes, amino-functionalized polypropylene 
membranes and glass surface. Libraries can thus be seen as a source of bioactive molecules 
that are selected on the basis of the biochemical properties pre-defined by appropriate assay 
settings. The more diverse will be the library, the higher will be the probability to select 
good “hits”. The concept of diversity is therefore of utmost importance in choosing a library 
for a particular screening and good libraries must first fulfill the requirement of highest 
diversity instead of the highest complexity. Molecules with overlapping structures will 
contribute little or nothing at all to the overall probability to find out a positive hit. The 
diversity of a library is generally associated to its complexity, that in turn depends on the 
number of different components. However this is not always true: small but smart libraries 
can display a higher diversity than libraries with a huge number of components. Indeed the 
synthesis of random combinatorial libraries of peptides generates a large number of “quasi-
duplicates” deriving from the strong similarity between several side chains. Using common 
amino acids, in L- or D- configuration, sequences where  Glu is replaced by Asp, Leu by Ile 
or Val, Gln by Asn and so on, can display very similar properties. Such residues, although 
being different in their propensity to adopt secondary structures, can be considered almost 
equivalent in terms of intrinsic physico-chemical properties, as for example the capacity to 
establish external interactions or to fit in a given recognition site. In large libraries, the need 
to manage large arrays of tubes and codes can puzzle the way  to the identification of lead 
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compounds and slows down the synthetic and deconvolution steps. To simplify the 
synthesis and deconvolution procedures without significantly affecting the probability to 
find out active peptides, we have reasoned on the general properties of L and D-amino 
acids, reaching a compromise between the need to maintain the highest possible diversity 
and that of reducing the number of building blocks. We have called these new libraries 
“Simplified Libraries”, intending with this any new ensemble of possible sequences 
achievable with a reduced and non redundant set of amino acids. The set of “non 
redundant” different residues (12 instead of 20) is chosen following several simple rules. 
Firstly “quasi-identical” groups of amino acids are selected: Asp and Glu; Asn and Gln; Ile 
and Val; Met and Leu; Arg and Lys; Gly and Ala; Tyr and Trp; Ser and Thr. Then, from each 
group, one is selected trying to keep a good distribution of properties, including 
hydropathic properties, charges, pKa, aromaticity. The cysteine is converted to the stable 
acetamidomethyl-derivative to prevent polymerization and to increase the number of polar 
residues within the final set. The distribution of residue molecular weights is also an 
important parameter in cases of deconvolution of the library by mass spectrometry 
approaches. The molecular weights do not overlap, allowing unambiguous assignment of 
sequences by tandem mass spectrometry. Using this set of amino acids in the L- or D- 
configuration, several libraries have been designed and synthesized (Marasco et al,  2008). 
2.2 Automated libraries characterization 
A key element for a successful screening of peptide libraries is the preparation of good 
quality libraries. Unclear screening results are often ascribed to the random generation of 
large populations of impurities, therefore even for very large mixture libraries, gross 
analytical characterizations must be performed to assess the relative amounts and the 
distribution of experimental molecular weight of library components. While classical 
analytical methods, as for example LC-MS, can be in most cases enough for the 
characterization of single compounds, more sophisticated techniques are required for the 
analysis of complex mixtures. The recent progresses in parallel separation methods, such as 
orthogonal chromatography, associated to synergic combinations of different detectors of 
complementary selectivities, have allowed the development of high-throughput analytical 
technologies based on traditional methods as HPLC, capillary electrophoresis (CE), NMR, 
FTIR, LC-MS, evaporative light scattering (ELSD), chemiluminescent nitrogen (CLND). A 
list of useful techniques is reported in Table 2.  
Mass spectrometry (MS) is the best method to assess compound identity and purity due to its 
sensitivity, speed and specificity. Electrospray ionization (ESI) coupled to quadrupole 
analyzers or Matrix Assisted Laser Desorption Ionization Time-Of-Flight (MALDI-TOF) are 
useful for peptide library analysis. LC-MS systems using ESI and different analyzers (single 
or triple quadrupoles, ion traps, TOF), offer the advantage of chromatographic separation 
prior to on-line mass analysis, thus enormously simplifying data interpretation. Single 
quadrupole instruments typically provide unit mass resolution and therefore do not resolve 
isobaric ions (i.e. two compounds with the same nominal mass but different exact mass), 
which are often encountered in combinatorial libraries. LC-MS systems equipped with ESI 
and TOF analyzers (ESI-TOF) or with combined quadrupole-TOF (Q-TOF) analyzers provide 
increased mass accuracies up to 5 ppm and great versatility for tandem mass analysis. 
Limitations of MS include the inability to distinguish isomers and, with the increase  
of potential molecular formulae, differences in masses are too close to measurement error.  
 Automation 
 
424 
 
Detection mode Advantages Disadvantages 
UV-absorbance 
spectroscopy 
 High sensibility and 
response linearity 
 Easy on-line integration 
 Relative purity 
measurements 
 Compounds have to bear 
chromophores 
 Responses depende on 
extinction coefficients 
Evaporative light 
scattering 
 Response factors of diverse 
compounds 
 Easy on-line integration 
 Relative purity 
measurements 
 Limited for compounds 
with MW>300 amu 
 Right response depends on 
geometry molecule 
Chemiluminescent 
nitrogen 
 Universal response to 
number of nitrogen 
structure 
 Quantitative purity (if 
used with an internal 
standards) 
 Easy on-line integration 
 Compounds must contain 
nitrogen 
MS 
 Excellent sensibility 
 Exact mass identification 
 Easy on-line integration 
 Response factors depend on 
compound ionizability and 
matrix effects 
 Limited resolution with 
compounds with a high 
MW 
NMR 
 Universal response 
indipendent from 
structure 
 Quantitative purity (if 
used with an internal 
standards) 
 Detailed structure 
information 
 Complex data interpretation 
 UV-absorbance Peak 
assignement difficult in 
presence of impurities 
 Difficult on-line integration 
Table 2. Rivelator Method for HTS Characterization Of Compound Libraries  
In addition to standard HPLC columns systems for interfacing to MS, several alternative 
separation techniques or platforms have been investigated for high-throughput purity 
analysis. An interesting application regards imaging time-of-flight secondary ion mass 
spectrometry (TOF-SIMS) to perform high-throughput analysis of solid phase synthesized 
combinatorial libraries. Also NMR techniques have been extensively utilized for the 
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identification and quantification of combinatorial compounds. NMR has the capability of 
elucidating compound structure and it is a quantitative detector whose response factor is 
directly proportional to the number of nuclei for a given signal, independent of molecular 
structure. Recently advances in NMR probe design have enabled sampling from smaller 
sample volumes and have significantly improved sample throughput overcoming some 
limitations of traditional NMR for combinatorial analysis included its low sensitivity, low 
sample throughput and complexity of data interpretation. The characterization of large 
mixture libraries has also been performed by pool amino acid analysis  and by pool N-
terminal sequencing techniques. Such techniques, though not providing single compounds 
purity and identity, can offer a rough but useful indication of equimolarity and 
representativeness of components. 
2.3 Assays preparation 
Automation is an important element in HTS's usefulness. Typically, an integrated robot 
system consisting of one or more robots transports assay-microplates from one station to 
another for sample and reagent addition, mixing, incubation and finally readout or 
detection. A HTS system can usually prepare, incubate, and analyze many plates 
simultaneously, further speeding the data-collection process. Currently HTS robots are able 
to test up to 100,000 compounds per day. The key labware or testing vessel of HTS is the 
microtiter plate: a small container, usually disposable and made of plastic, that features a 
grid of small, open divots called wells. Modern microplates for HTS generally have either 
384, 1536, or 3456 wells. These are all multiples of 96, reflecting the original 96 well 
microplate with 8 x 12 9mm spaced wells. Most of the wells contain experimentally useful 
matter, often an aqueous solution of dimethyl sulfoxide (DMSO) and some other chemical 
compounds, the latter of which is different for each well across the plate. The other wells 
may be empty, intended for use as optional experimental controls. A screening laboratory 
typically holds a library of stock plates, whose contents are carefully catalogued, and each of 
which may have been created by the same lab or obtained from a commercial source. These 
stock plates themselves are not directly used in experiments; instead, separate assay plates 
are created as needed. An assay plate is simply a copy of a stock plate, created by pipetteing 
a small amount of liquid (often measured in nanoliters) from the wells of a stock plate to the 
corresponding wells of a completely empty plate. To prepare an assay each well of the plate 
is filled with some quantity of a protein, or an animal embryo. After some incubation time 
has passed to allow the biological matter to absorb, bind to, or otherwise react (or fail to 
react) with the compounds in the wells, measurements are taken across all the plate's wells, 
either manually or by a machine. Manual measurements are often necessary when the 
researcher is using microscopy to (for example) seek changes or defects in embryonic 
development caused by the wells compounds, looking for effects that a computer could not 
easily determine by itself. Otherwise, a specialized automated analysis machine can run a 
number of experiments on the wells. In this case, the machine outputs the result of each 
experiment as a grid of numeric values, with each number mapping to the value obtained 
from a single well. A high-capacity analysis machine can measure dozens of plates in the 
space of a few minutes like this, generating thousands of experimental datapoints very 
quickly. Depending on the results of this first assay, the researcher can perform follow up 
assays within the same screen by "cherrypicking" liquid from the source wells that gave 
interesting results  into new assay plates, and then re-running the experiment to collect 
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further data on this narrowed set, confirming and refining observations. Problems 
associated with screening robotics have included long design and implementation time, 
long manual to automated method transfer time, non-stable robotic operation and limited 
error recovery abilities. These problems can be attributed to robot integration architectures, 
poor software design and robot–workstation compatibility issues (e.g., microplate readers 
and liquid handlers). Traditionally, these integrated robot architectures have involved 
multiple layered computers, different operating systems, a single central robot servicing all 
peripheral devices, and the necessity of complex scheduling software to coordinate all of the 
above. Usually robot-centric HTS systems have a central robot with a gripper that can pick 
and place microplates around a platform. They typically process between 40 and 100 
microplates in a single run (the duration of the run depends on the assay type). The screener 
loads the robotic platform with microplates and reagents at the beginning of the experiment 
and the assay is then processed unattended. Robotic HTS systems often have humidified 
CO2 incubators and are enclosed for tissue culture work. Like in assembly-line 
manufacturing, microplates are passed down a line in serial fashion to consecutive 
processing modules. Each module has its own simple pick and place robotic arm (to pass 
plates to the next module) and microplate processing device. The trend towards assay 
miniaturization arose simultaneously with move towards automation from the direct need 
to reduce development cost. Although at present most HTS is still carried out in 96-well 
plate format, the move towards 384-well and higher density plate formats is well taking 
place. Instrumentation for accurate, low-volume dispensing into 384-well plates is 
commercially available, so they are sensitive plate-readers that accommodate this format. 
The combination of liquid handling automation and information management processes 
supports the entire compound management cycle from compound submission to delivery of 
assay ready compound plates. The compound management often consists in the 
organization of hundreds of thousands of compounds (small molecules, natural products 
and peptide libraries in different formats). Compounds are stored offline in an automated 
compound store in 96-well tube format and online in 384-well format for hitpicking 
operations, 1536-well for HTS operations. Often there are dedicated LC-MS systems with 
multimode mass spectrometry (ESI, APCI, ELSD) for quality control of incoming HTS 
compound libraries and hit confirmation efforts. This platform is designed for automated 
analysis and generates database-ready reports. 
2.4 Screening assays 
Assays are either heterogeneous or homogeneous. Heterogeneous assays are a bit complex, 
requiring additional steps like filtration, centrifugation etc. beyond the usual steps like fluid 
addition, incubation and reading. Homogeneous assays are simpler, consisting of the latter 
three usual steps - this may also be called a true homogeneous assay. However at times 
homogeneous assays could be complex due to the need for multiple addition and different 
incubation times. Though homogeneous assays are advantageous, many companies prefer 
to continue to use heterogeneous assay, eyeing their better precision over its counterpart, 
though it is true only in few number of cases. The driving force for use of homogeneous 
assays is the lower number of steps, which will help reduce assay cost. This simplicity may 
also reduce the robotic complexity requirement for automation. When performing HTS of 
free compounds in solution, automation, miniaturization and very sensitive detection 
methodologies are required. Different approaches such as ELISA, cell-based cytotoxic, 
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antimicrobial, radiometric and fluorescence-based assays, affinity chromatography 
methodologies can be used. Fluorescence-based techniques are likely to be among the most 
important detection approaches used for HTS due to their high sensitivity and amenability 
to automation, given the industry-wide drive to simplify, miniaturize, and speed up assays. 
Fluorescence resonance energy transfer (FRET), fluorescence polarization (FP), and 
fluorescence correlation spectroscopy (FCS) are indeed already broadly utilized for 
screenings of large collections of compounds and many optical readers capable of handling 
multi-well plates are commercially available. FRET is based on energy transfer between 
appropriate energy donor and acceptor molecules. It is typically used in protein-protein 
interaction studies where one protein partner is labelled with a fluorescence donor and the 
other one is labelled with an appropriate fluorescence acceptor molecule. The donor has the 
specific property of being excitable, emitting a fluorescence photon at a wavelength that is 
able to in turn excite the acceptor. When the two proteins interact and the system is excited 
at the donor excitation wavelength, a specific fluorescence emission at the acceptor emission 
wavelength is recorded. The energy transfer occurs only when the donor-acceptor pair is 
within a minimum distance, the Förster distance (the distance at which energy transfer 
efficiency is half-maximal), which is around 50 Å. When performing a screening assay, if a 
library component is able to disrupt the protein-protein interaction, the effect can be 
quantitatively measured by a reduction of the FRET effect. Similar assays can be performed 
using the Time Resolved FRET (TR-FRET) whereby the fluorescence of the acceptor 
molecule has a duration on the milliseconds time scale, allowing fluorescence measurement 
after a short time delay to remove interference by the excitation energy or by inhibitors. TR-
FRET can be integrated on large time intervals to increase sensitivity. Typical donor-
acceptor molecules are the Allophycocyanin-Europium chelates or the fluorescein - Terbium 
chelates. FRET can also be used to determine enzyme activity using internally quenched 
probes. In these systems short peptides corresponding to the sequence for a natural cleavage 
site of the enzyme is synthesized and labelled at opposite ends with appropriate donor and 
quencher pairs. Before cleavage, donor and quencher are very close and the effective 
fluorescence emitted is low; once the two parts drift apart, the fluorescent signal increases. 
This approach has been successfully utilized to screen the substrate specificity of an alkaline 
serine proteinase.  FP experiments allow measurements of changes in the emitted light 
intensity of small labelled probes on binding to larger molecules. The sample is excited with 
polarized light and, when a binding equilibrium is established, the observed polarization of 
the emitted light increases. In FCS the main detected parameter is the spontaneous intensity 
fluctuations caused by the minute deviations of the small system from the thermal 
equilibrium. FCS is an emerging technique for HTS. In this case, measurements are carried 
out using confocal optics to provide the highly focused excitation light. It is used to monitor 
binding interactions as well as other molecular events. At times it was reported that assays 
for biological targets cannot be conveniently designed to fit with standard cellular or 
biochemical assay formats. For example, in the search for new antibacterial agents, genomic 
experiments have indicated a large number of proteins that are essential for the survival of 
the bacterium but whose function in the cell is unknown. In this case there is no known 
biological function that will allow the design a biochemical or cellular screen. To screen 
these types of target, an alternative to conventional chemical or cellular screenings may be 
used. One alternative screening approach that does not require knowledge or analysis of the 
biological function of the target of choice is direct measurement of compound interaction 
with protein. A range of techniques are available to measure the direct binding events such 
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as NMR, SPR and calorimetry. One advantage afforded by NMR is that it can provide direct 
information on the affinity of the screening compounds and the binding location of protein. 
The structure-activity relationship acquired from NMR analysis can sharpen the library 
design, which will be very important for the design of HTS experiments with well-defined 
drug candidates. Affinity chromatography used for library screening will provide 
information on the fundamental processes of drug action, such as absorption, distribution, 
excretion, and receptor activation; also the eluting curve can give directly the possibility of 
candidate drug. SPR can measure the quantity of a complex formed between two molecules 
in real-time without the need for fluorescent or radioisotopic labels. SPR is capable of 
characterizing unmodified biopharmaceuticals, studying the interaction of drug candidates 
with macromolecular targets, and identifying binding partners during ligand fishing 
experiments. They indeed allow real-time detection of soluble peptide binding to different 
biomolecules, like proteins, nucleic acids or sugars and also to cell membranes or whole 
cells. In addition, they allow the one-step measurement of kinetic rates and affinity of 
binding, thus providing an affinity ranking of molecules peptides. 
2.5 Data analysis 
In validating a typical HTS assay, unknown samples are assayed with reference controls. 
The sample signal refers to the measured signal for a given test compound. The negative 
control (usually referred to as background) refers to set of individual assays from control 
wells that give minimum signals. The positive control refers to the set of individual assay 
from control wells that give maximum signals. In validating the assay, it is critical to run 
several assay plates containing positive and negative control in order to assess 
reproducibility and signal variation at two extremes of the activity range. The positive and 
negative control data can then be used to calculate their means and standard deviations 
(SD). The difference between the mean of the positive controls and the mean of the negative 
controls defines the dynamic range of the assay signal. The variation in signal measurement 
for samples, positive control, and negative controls (i.e., SDs) may be different. The mean 
and SD of all the test samples are largely governed by the assay method and also by intrinsic 
properties of the compound library. Because the vast majority of compounds from an 
unbiased library have very low or no biological activity, the mean and SD of all the sample 
signals should be close to those of the positive controls for inhibition/antagonist type assays 
and near to those of the negative controls for activation/agonist types assays.  
The Z-factor is a measure of statistical effect. It was proposed for use in HTS to judge 
whether the response in a particular assay is large enough to warrant further attention. The 
Z-factor is defined by four parameters: the means (μ) and standard deviations (σ) of both the 
positive (p) and negative (n) controls (μp, σp, and μn, σn). Given these values, the Z-factor is 
defined as: 
 3
Z-factor=1-
p n
p n
 
 
 
  
Generally HTS suffers from two types of errors false positives and negatives. A poor 
candidate or an artifact gives an anomalously high signal, exceeding an established 
threshold. While a perfectly good candidate compound is not flagged as a hit, because it 
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gives an anomalously low signal. Moreover, a low degree of relevance of the test may 
induce a high failure rate of type. Much more attention is given to false-positive results than 
to false-negative results. Some of the false positives are promiscuous compounds that act 
non competitively and show little relationship between structure and function. 
In HTS each biochemical experiment in a single well is analyzed by an automated device, 
typically a plate reader or other kind of detectors. The output of these instruments comes in 
different formats depending on the type of reader. Sometimes multiple readings are 
necessary, and the instrument itself may perform some initial calculation. These 
heterogeneous types of raw data are automatically fed into the data management software. 
In the next step raw data are translated in contextual information by calculating results. 
Data on percentage inhibition or percentage of control are normalized with values obtained 
from the high and low controls present in each plate. The values obtained depend on the 
method used for the normalization step (e.g. fitting algorithms used for dose-response 
curve) and have to be standardized for screens. All the plates that fail against one or more 
quality criteria are flagged and discarded. A final step in the process requires the 
experimenter to monitor visually the data that have been flagged, as a final quality check. 
This is a fundamental step to ensure the system has performed correctly. In addition to 
registering the test data, all relevant information about the assay has to be logged, e.g. the 
supplier of reagents, storage conditions, a detailed protocol, plate layout, and algorithms for 
the calculation of results. Each assay run is registered and its performance documented. 
HTS will initially deliver hits in targeted assays. Retrieval of these data has to be simple and 
the data must be exchangeable between different project teams to generate knowledge from 
the total mass of data. 
3. Virtual screening  
Even with HTS, the discovery of new lead compounds largely remains a matter of trial and 
error. Although the number of compounds that can be evaluated by HTS methods is 
apparently large, these numbers are small in comparison to the astronomical number of 
possible molecular structures that might represent potential drug-like molecules. Often, far 
more compounds exist or can be synthesized by combinatorial methods than can be 
reasonably and affordably evaluated by HTS. As the costs of computing decreases and as 
computational speeds increase, many researchers have directed efforts to develop 
computational methods to perform “virtual screens” of compounds. Thus since  performing 
screens in silico can be faster and less expensive than HTS methods, virtual screening 
methods may provide the key to limit the number of compounds to be evaluated by HTS to 
a subset of molecules that are more likely to yield “hits” when screened. For the practical 
advantages of virtual screening to be realized, computational methods must excel in speed, 
cheapness, and accuracy. Striking the right balance of these criteria with existing tools 
presents a formidable challenge. An inspiring example study  is related to the structure-
based virtual screening applied to the selection of new thyroid hormone receptor 
antagonists when only a related receptor structure is available. Receptor-based virtual 
screening uses knowledge of the target protein structure to select candidate compounds 
with which it is likely to favorably interact (Schapira et al., 2003). Even when the structure of 
the target molecule is known, the ability to design a molecule to bind, inhibit, or activate a 
biomolecular target remains a daunting challenge. Although the fundamental goals of 
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screening methods are to identify those molecules with the proper complement of shape, 
hydrogen bonding, electrostatic and hydrophobic interactions for the target receptor, the 
complexity of the problem is in reality far greater. For example, the ligand and the receptor 
may exist in a different set of conformations when in free solution than when bound. The 
entropy of the unassociated ligand and receptor is generally higher than that of the 
complexes, and favorable interactions with water are lost upon binding. These energetic 
costs of association must be offset by the gain of favorable intermolecular protein–ligand 
interactions. The magnitude of the energetic costs and gains is typically much larger than 
their difference, and, therefore, potency is extremely difficult to predict even when relative 
errors are small. While several methods have been developed to more accurately predict the 
strength of molecular association events by accounting for entropic and solvation effects, 
these methods are costly in terms of computational time and are inappropriate for the 
virtual screening of large compound databases. The challenge in developing practical 
virtual screening methods is to develop an algorithm that is fast enough to rapidly evaluate 
potentially millions of compounds while maintaining sufficient accuracy to successfully 
identify a subset of compounds that is significantly enriched in hits. Accordingly, structure-
based screening methods typically use a minimalist ‘‘grid’’ representation of the receptor 
properties and an empirical or semiempirically derived scoring function to estimate the 
potency of the bound complex (Schulz-Gasch & Stahl, 2003). Several programs now employ 
a range of scoring functions, but it is often difficult to assess their effectiveness on difficult 
‘‘real-world’’ problems.  Virtual screening based on receptor structure therefore has the 
distinct advantage of aiding the discovery of new antagonist structural classes or 
pharmacophores. First, and most importantly, from the many  case studies published over 
the past decade, it has become evident that the applicability and thus the usefulness of a 
particular virtual screening method for a given drug discovery project depends on the 
macromolecular target being investigated. Thus it seems more appropriate to consider 
virtual screening from a problem-centric rather than a method centric perspective. 
Depending on what is already known about a target and its ligands, different approaches to 
virtual screening — and consequently different sets of methods — are preferred. In addition, 
some virtual screening methods that have been reported might be premature or simply not 
sufficiently accurate. Second, the perceived success or failure of virtual screening in a 
particular organization depends on the depth and mode of integration of virtual screening 
in the organization’s hit identification process, and whether expectations are realistic. For 
example, an important factor for the chances of success of virtual screening could be 
whether hits with interesting characteristics, such as structural novelty and/or patentability, 
can be sufficiently nurtured by medicinal chemists to produce leads that can compete with 
those arising from HTS. Indeed, this is typically the scenario for hits arising from alternative 
lead discovery approaches such as fragment-based screening. Third, a major achievement of 
virtual screening so far has been to help eliminate the bulk of inactive compounds (negative 
design), rather than to actually select bioactive molecules for a given target (positive design). 
Although this statement is a simplification it highlights the extent of the challenges for 
developing improved virtual screening methods.  
It will be important to systematically determine which ligand–receptor interactions are 
amenable to such an approach and which require other or additional features to be 
considered indeed, dynamic descriptions of molecules will have to replace our 
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predominantly static view of both targets and ligands. Molecular dynamics simulations can 
sample conformational ensembles of targets and ligands. However, some of the popular 
force-field approaches used to describe the energetics of molecular systems might be 
inadequate for drug design. Furthermore, although in general it might be more valuable to 
identify ligand chemotypes for which receptor–ligand complex formation is dominated by 
enthalpy changes rather than entropy changes, improvements are required to  allow for a 
more accurate estimation of both enthalpic and entropic contributions (Freire, 2008). The 
thermodynamics of ligand–receptor interactions are commonly treated in a similar way as 
molecular reactions, and this may not always be appropriate. How can we reliably and 
efficiently predict that some protein–ligand interactions become stronger with increasing 
temperature, or identify the role of buried water on ligand binding? Questions like these 
must be answered by computational chemistry as the forces that govern ligand–receptor 
interactions are only understood at a rudimentary level: flexible fit phenomena, the role of 
water molecules, protonation states in proteinaceous environments, and the entropic and 
enthalpic contributions and compensations upon complex formation are not satisfactorily 
addressed by the existing virtual screening methods. In this respect, advanced and 
specialized computer hardware might enable extended (>100 ns) dynamics simulations of 
macromolecular targets and receptor–ligand complexes on a routine basis, which might help 
our understanding of allosteric effects and flexible fit phenomena of druglike ligands and 
effector molecules. As a consequence, modelling of dynamic molecular features (in contrast 
to static properties such as molecular mass, logP and other time-invariant molecular 
properties), which cannot be accurately achieved at present, could improve the accuracy of 
future predictions of novel bioactive compounds.  
4. Fragment screening 
Fragment-based drug discovery has proved too to be a very useful approach particularly in 
the hit-to-lead process, acting as a complementary tool to traditional HTS. Over the last ten 
years, fragment-based drug discovery has provided in excess of 50 examples of small 
molecule hits that have been successfully advanced to leads and therefore resulted in useful 
substrate for drug discovery programs. The unique feature of fragment-based drug 
discovery is the low molecular weight of the hit. It has the potential to supersede traditional 
HTS  based drug discovery for molecular targets amenable to structure determination. This 
is because the chemical diversity coverage is better accomplished by a fragment collection of 
reasonable size than by larger HTS collections. Fragments represent smaller, less complex, 
molecules than either drug compounds or typical lead series compounds. It is now widely 
acknowledged within the pharmaceutical and biotech industries that weakly active 
fragment hit molecules can be efficiently optimised into lead compound series if structural 
insight is obtained at the outset for the binding interaction between each fragment hit and 
the target protein of interest. This is supported by recent reports of the progression into 
human clinical trials of drug molecules developed from weakly active fragment starting 
points (Jhoti et al., 2007). Fragment-based drug discovery can explore the drug-like chemical 
diversity space in an efficient and effective manner. Two key factors govern this approach, 
firstly the coverage of fragment chemical diversity space during the screening stage and 
then, that drug chemical diversity space is explored in an efficient iterative fashion during 
the optimisation stage as fewer combinations need to be evaluated than through a purely 
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random screening and undirected optimisation approach. For example, a fragment 
collection of 10 000 molecules may virtually represent the diversity of one billion molecules 
if one considers the combinatorial power of fragment merging or linking (e.g. by assuming 
two adjacent binding sites to which fragments bind and 10 different possibilities of fragment 
linking) but only a small part of the larger chemical space defined by fragment merging and 
linking needs to be explored in the structure- directed elaboration of fragments into leads. 
Employing fragment-based drug discovery a relatively small number of low molecular 
weight fragment molecules can provide a higher degree of sampling of the chemical 
diversity space for fragments than a very large number of higher molecular weight 
compounds is able to sample the respective chemical diversity space for drug-like 
compounds. Furthermore lower molecular weight molecules exhibit reduced complexity 
than the larger molecules in drug-like collections and it can be hypothesized a  model to 
rationalise ligand–receptor interactions in the molecular recognition process. Accordingly 
the theoretical probability of a useful interaction falls dramatically with increasing 
molecular complexity of the ligand. The selection of the fragment screening method is of key 
importance since there are two general factors that have an impact for all methods. The first 
is sensitivity of the screening method and the second is throughput. Sensitive screening 
methods enable weakly active fragment molecules of lower molecular weights to be 
identified as hit compounds and so fragment libraries with a lower molecular weight range 
can be used. On the contrary the use of a low throughput screening method necessitates the 
use of a smaller fragment library with a concomitant sparser coverage of fragment chemical 
diversity space. Perhaps the most elegant method of fragment screening is by X-ray 
crystallography, in that it provides directly structural information on the interaction 
between fragment ligands and the protein target. However, owing to the method’s low 
throughput, even when fully automated, the technique can only be effectively applied to 
targets for which a robust crystallographic system is available that allows soaking of 
preformed crystals with fragment cocktail mixtures of up to 10 compounds at high 
concentrations. This requirement imposes two key limitations: in the number of evaluable 
fragment compounds, typically limited to no more than 1000 fragments, and for this,  there 
is a significant possibility of missing active fragments owing to the protein being locked into 
a conformation, in the crystals used for the soaking studies, that does not allow the 
interaction of fragments that require induced fit to bind. Although, no data are available on 
the false negative rate for fragment screening by X-ray crystallography it may be significant 
for certain targets. Each fragment screening technique has its advantages; X-ray 
crystallography provides immediate structural information, NMR provides binding site and 
affinity information of a very high quality while bioassays provide functionally relevant 
activity data for larger collections of fragments. The best approach is to combine the 
methods in order to maximize their value to fragment-based drug discovery. NMR and 
biochemical screening of fragments are complementary orthogonal methods that can be 
used individually or in concert to provide the most effective way of addressing each new 
biological target of interest. The strength of biochemical screening is that its throughput 
allows large fragment collections to be screened in a short length of time. This ensures that 
the most ligand efficient diverse starting points are available for medicinal chemists to select 
for subsequent optimisation. A further advantage is that screening related targets using 
generic biochemical assay formats enables insights into target selectivity from the outset. 
The large number of fragment hits that are obtained through use of biochemical screening of 
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large fragment libraries can be effectively triaged ahead of crystallography by the use of 
protein NMR. Thus, the most effective way to perform fragment screening is not to rely on a 
single method but to use orthogonal methods in concert. 
5. Conclusion  
HTS is the most widely applicable technology delivering chemistry entry points for drug 
discovery programs, however it is well recognized that even when compounds are 
identified from HTS they are not always suitable for further medicinal chemistry 
exploration. It is evident that in the future the overwhelming number of emerging target 
will dramatically increase the demand put on HTS and that this will call for new hit and 
lead generation strategies to curb costs and enhance efficiency. The collections of large 
pharmaceutical companies are approaching approximately one million entities, which 
represents historical collections (intermediates and precursors from earlier medicinal or 
agrochemical research programs), natural products and combinatorial chemistry libraries. 
This about one order of magnitude higher than ten years ago when HTS and combinatorial 
chemistry first emerged. However today purchasing efforts in many pharmaceutical 
companies are directed towards constantly improving and diversifying the compounds 
collections and making them globally available for random HTS campaigns. The 
combinatorial explosion- meaning the virtually number of compounds that are synthetically 
tractable-has fascinated and challenged chemists ever since the inception of the concept. 
Independent of the library designs, the question of which compounds  should be made from 
the huge pool of possibilities always emerges immediately, once the chemistry is established 
and the relevant building blocks are identified. The original concept of “synthesize and 
test”, without considering the targets being screened, was frequently questioned by the 
medicinal chemistry community and is nowadays considered of lower interest due to the 
unsatisfactory hit rates obtained so far. As a consequence there is now a clear trend to move 
away from huge and diverse “random” combinatorial libraries towards smaller and focused 
drug-like subsets. Hit and lead generation are key processes involved in the creation of 
successful new medicinal entities and it is the quality of information content imparted 
through their exploration and refinement that largely determines their fate in the later stages 
of clinical development.  The combination of virtual screening and parallel and medicinal 
chemistry, in conjuction with multi-dimensional compound-property optimization, will 
generate a much-improved basis for proper and timely decisions about which lead series to 
pursue further. 
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